Madison, WI – February 21, 2008 – BellBrook Labs, a leading provider of high throughput screening tools for the drug discovery industry, today announced that the U.S. Patent and Trademark Office issued a patent (U.S. Pat. No. 7,332,278) to BellBrook Labs the Transcreener™ HTS Assay platform. 

Our proprietary Transcreener™ HTS Platform was developed to move more new targets into HTS more rapidly, and to streamline selectivity profiling within a target family.  It relies on homogenous fluorescent immunodetection of nucleotides, including ADP, UDP, AMP and GMP, which are formed by thousands of cellular enzymes.  Among these are group transferase families, such as kinases, ATPases and glycosyltransferases, that catalyze the covalent regulatory reactions that are central to cell signaling.  Each Transcreener™ Assay provides a generic detection method for multiple enzyme families.  This means that you can focus on evaluating new therapeutic strategies and optimizing lead molecules rather than on time-consuming assay development for individual targets.  The Transcreener™ platform is unique in this regard; there is no other HTS platform with the potential to eliminate so much costly assay development for so many drug targets.  Since introduction of the first Transcreener assays, the platform has been rapidly validated and adopted by pharmaceutical and biotechnology screening labs around the world.

About BellBrook Labs
Founded in 2002, BellBrook Labs provides the pharmaceutical industry with high throughput screening (HTS) tools that accelerate the discovery of effective therapies.  In 2005, with the development of the Transcreener™ Assay Platform, BellBrook Labs introduced HTS methods that removed the assay development bottlenecks restricting access to many promising therapeutic, ADME and safety drug targets. Data generated from these assays allows better prediction about how patients will respond to drugs and improves the business case for drug target testing and the development of new drug treatments. 

BellBrook Labs Contact:
Robert Lowery
President & CEO
608-227-4501
bob.lowery@bellbrooklabs.com

Biology at Work